In NAFLD, possibly due to a decrease in TSAT, the liver reduces hepcidin mRNA expression in response to this change, reducing ferroportin degradation, allowing more iron to be transported into the blood, and increasing iron bioavailability [17, 75]. This evidence concerns the gene SLC40A1 and metabolic dysfunction-associated steatotic liver disease.